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Direct Validation of In Vivo Localized 13C MRS
Measurements of Brain Glycogen
Hongxia Lei,1 Florence Morgenthaler,1 Tianwen Yue,1 and Rolf Gruetter1,2
With the use of localized 13C MRS in conjunction with [1-13C]-D-
glucose infusion, it is possible to study brain glycogenmetabolism
in vivo. The purpose of this study was to validate in vivo 13C MRS
measurements by comparing them with results from a standard
biochemical assay. To increase the [1–13C] glycogen concentra-
tion, 11 rats were subjected to an episode of acute hypoglycemia
followed by a mild hyperglycemic recovery period during which
[1-13C]-D-glucose was infused. The total brain [1-13C] glycogen of
the same animal was determined from the enzymatically deter-
mined total brain glycogen content, which was ﬁxed by focused
microwave irradiation (4 kW in 1.4 s) immediately after the end of
the in vivo NMR measurements. The corresponding isotopic en-
richment (IE) of glycogen was measured by in vitro 1H MRS of
protons bound to glucose C1-. The in vivo [1-13C] glycogen
concentration was strongly correlated to the in vitro [1-13C] gly-
cogen content determined by biochemical measurement in a lin-
ear manner (R  0.79). The results are consistent with the notion
that localized 13C MRS measurements closely reﬂect 13C glyco-
gen content in the brain. Magn Reson Med 57:243–248, 2007.
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Brain glycogen is the largest glucose storage form in the
central nervous system (CNS) and is increasingly being
recognized as an important factor in brain energy metabo-
lism (1,2). For example, its concentration exceeds that of
brain glucose by severalfold, and depletion of glycogen
signiﬁcantly affects neuronal survival (3). It has been re-
ported that brain glycogen may be higher than previously
thought (4–6), which may be explained by the fact that
brain glycogen is a highly labile metabolite and requires a
highly sensitive and accurate method for its biochemical
measurement.
We recently developed a localized 13C MRS method to
quantify the 13C brain glycogen signal. In previous studies
brain glycogen metabolism was assessed in vivo with 13C-
labeling to enhance sensitivity (7,8). To date, in vivo 13C
MRS is the only method available to assess brain glycogen
content and metabolism noninvasively. In vivo brain gly-
cogen metabolism studies using 13C MRS suggested that
glycogen plays an important role as an emergency supply
of energy during limited glucose transport that occurs in
acute hypoglycemia (9). The observed supercompensation
of brain glycogen following hypoglycemia suggests a pro-
found effect of acute hypoglycemia on brain glycogen me-
tabolism and content, which may affect glucose-sensing
and may explain in part the defective counterregulation
observed after a single episode of insulin-induced hypo-
glycemia (1). The 13C MRS method for the localized mea-
surement of brain glycogen metabolism and content was
expanded to in vivo human studies (10).
In liver, muscle, and heart, a variable proportion of total
glycogen has been reported to exist in a low-molecular-
weight form, namely proglycogen (400 kDa), and in the
form of macroglycogen (107 Da) (11). Therefore, the brain
glycogen signal is likely to have complex NMR relaxation
properties (12) that can affect the reliability of its measure-
ment in vivo, even though the majority of glycogen, if not
all, can be detected by 13C NMR spectroscopy in the heart
(13), muscle (14), and liver (15,16).
Therefore, in vivo localized 13C MRS measurement of
brain glycogen should represent the total 13C glycogen in
the brain. The aim of this study was to validate in vivo 13C
NMR measurements of brain glycogen C1 by comparison
with a standard biochemical assay.
MATERIALS AND METHODS
Animal Preparation
All in vivo studies were performed according to the guide-
lines of the University of Minnesota for the care and use of
laboratory animals, and were approved by the Institutional
Animal Care and Use Committee (IACUC). Eleven male
Sprague-Dawley rats (150–175 g; Harlan Inc., WI, USA)
were obtained 2 weeks before the studies. On the day of
the experiment, the rats (252  2 g, mean  SD) had been
subjected to a 16-hr overnight fasting period. They were
prepared under 2% isoﬂurane anesthesia in a 2:1 mixture
of nitrous oxide (N2O) and oxygen (O2), and ventilated
with a pressure-driven ventilator (Kent Scientiﬁc Inc., CT,
USA). Both femoral arteries were catheterized for blood
sampling (plasma glucose and blood gas) and both femoral
veins were catheterized for administration of test sub-
stances (-chloralose, insulin and [1-13C]-D-glucose). Once
vascular access was secured, anesthesia was switched to
-chloralose (Sigma-Aldrich Inc., MO, USA) with a 40-
mg/kg bolus followed by a26.7-mg/kg/hr continuous i.v.
infusion.
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Shortly thereafter, insulin (1 U/mL, Humulin® R; Lilly
Inc., IN, USA) was administered to reach the target hypo-
glycemic condition of plasma glucose  2 mM. Simulta-
neously, a 20% w/v solution of [1-13C]-D-glucose (Isotec
Inc., OH, USA; CIL Inc., MA, USA) was infused at a rate
ranging from 0.1 to 1 mL/hr to avoid plasma glucose falling
below 1 mM. Immediately after 2 hr of acute hypoglyce-
mia, a 13C glucose bolus followed by an adjustable contin-
uous glucose infusion rate was used to establish mild
hyperglycemia at a target concentration of 11 mM. Dur-
ing the second hour of this hyperglycemia recovery period,
the animals were stereotaxically ﬁxed with ear bars in an
in-house-made holder, as described previously (8), and
placed in the magnet.
Throughout the entire study period, the animals’ body
temperature was maintained at 37°C by warm water circu-
lation (RTE-101 bath circulator; Thermo NESLAB, NH,
USA) based on feedback from a rectal temperature probe
(Cole Palmer Inc., IL, USA.). During the hypoglycemic
study, arterial blood was withdrawn at 5–10-min intervals
and spun down to obtain plasma glucose levels with an
Analox GM7 analyzer (Analox Instruments, MA, USA).
Concurrently, physiological parameters (i.e., PaO2, PaCO2
and pH) were maintained based on measurements of with-
drawn arterial blood with a blood gas analyzer (Rapidlab
248; Bayer Corp., UK) at 30-min intervals, which were
adapted to be the sampling intervals during hyperglyce-
mia.
Localized 13C MRS Measurement of In Vivo 13C Glycogen
of Rat Brain
All in vivo MRS studies were performed in a horizontal
9.4-T/31-cm magnet (Magnex Scientiﬁc, UK) with an
11-cm-diameter gradient coil capable of switching to
300 mT/m in 500 s, interfaced with an INOVA console
(Varian Inc., CA, USA). A quadrature 1H radiofrequency
(RF) 14-mm-diameter coil and a linear polarized, three-
turn 11-mm-diameter 13C RF coil (17,18) were used as the
transceiver. A sphere containing 99% 13C-enriched formic
acid (FA) was located at the center of the 13C coil as an
external reference, and the coil was placed on the animal’s
head as described previously (7,8,18). Fast Automatic
Shimming Technique by Mapping Along Projections
(FASTMAP) shimming with echo-planar imaging (EPI)
readout (19) was applied to adjust B0 ﬁeld homogeneity in
a nominal 440 L volume of interest. The Single-shot
Inversion Recovery based Non-Echo (SIRENE) sequence
(7) was applied for 3D localization with optimized outer
volume suppression (e.g., for glycogen, the inversion time
(TI) was 0.11 s) (7,8,18) to ensure elimination of signals
from noncerebral tissue, and bilevel WALTZ-16 RF pulses
were applied at the water frequency for generation of a
nuclear Overhauser effect (NOE) and for decoupling dur-
ing acquisition (7).
Twelve 64-scan localized 13C MR spectra (repetition
time (TR)  1 s) acquired during the last half hour of
hyperglycemia recovery were summed, apodized by 20-Hz
exponential line-broadening, zero-ﬁlled, and Fourier
transformed. The glycogen C1 signal intensity (IGlyc
invivo) was
ﬁtted using built-in spectrometer software (Varian Inc.)
with a ﬁxed linewidth obtained from the spectrum ob-
tained by summing all acquisitions during the entire ex-
periment. IGlyc
invivo was quantiﬁed using the external reference
method, based on the measurement of the signal from a
phantom containing 400 mM of natural abundance oyster
glycogen (Sigma-Aldrich Inc.) (IGlyc
ref ) under identical exper-
imental conditions as for the in vivo studies (8), including
temperature. The glycogen C1 signal intensity in the phan-
tom was slightly temperature-dependent, as judged from
separate measurements at 21°C, 37°C, and 55°C using the
same settings as for the in vivo studies described above
except that no localization, no decoupling, and TR  20 s
were used. The in vitro oyster glycogen C1 signal intensity
at ambient room temperature (21°C) was reduced by16%
compared to that at 37°C, which was 8% lower than that
at 55°C. In vivo 13C glycogen content ([13C-Glyc]invivo) was
calculated based on Eq. [1] from IGlyc
ref . The in vivo signal
was corrected with a small correction factor (15%),
which included measured differential coil loading deter-
mined from the obtained the FA signals in reference stud-
ies (IFA
ref ) and in vivo experiments (IFA
invivo), and NOE/T1 ef-
fects assessed from the fully relaxed glycogen signal as in
previous studies (7,8):
[13C  Glyc]invivo 
IGlyc
invivo  IFA
ref  400mM  1.1%
IGlyc
ref  IFA
invivo .
[1]
The glycogen solution was 400 mM natural abundance
(1.1%) oyster glycogen, and 1 mM  1 mol/g was as-
sumed.
Enzymatic Determination of In Vitro Glycogen
Concentration
Shortly after completion of the in vivo 13C MRS measure-
ment (10 min), the animals were carefully killed with the
use of a focused microwave ﬁxation device (Gerling Ap-
plied Electronics, Modesta, CA) at 4 kW within 1.4 s (6).
The brain (excluding cerebellum) was removed from the
skull and stored in a –80°C freezer (Thermo Forma, OH,
USA) for further processing.
Within 8 weeks, the frozen brains were pulverized un-
der liquid N2 using a mortar and a pestle. The well-mixed
brain powder was separated into two 200-mg samples to
determine brain glycogen content using a standard bio-
chemical assay (20), as follows: Brieﬂy, 500 L of 0.03 M
HCl were added to each sample, homogenized well
(25-kHz ultrasonic processor, Cole Parmer Inc.), and
heated for 45 min at 8090°C in a water bath. From each
sample, two identical 200-L aliquots were taken and
treated in exactly the same way, except that 5 L of 5-mM
sodium acetate was added to the “minus” sample (to yield
tissue glucose concentration), and 5 L of amyloglucosi-
dase (Roche Diagnostics Corp., IN, USA) solution was
added to the “plus” sample (to yield total tissue glucosyl
concentration). The samples were pH-adjusted to 5 and
incubated for 2 hr at 37°C in a reciprocal water-bath
shaker (New Brunswick Scientiﬁc Co., Inc., NJ, USA).
Glucose levels were determined at room temperature
and the readouts were ensured to be in the linear range of
the analyzer (Analox GM7 analyzer, see above). The glu-
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cose concentration of the brain extracts ([Glc], mol/g wet
weight) for each sample was calculated from the glucose
analyzer readout ([Glc]readout) by correcting for dilution
using the following equation:
[Glc]  [Glc]readout 
Wbrainpowder 	 WHCl
Wbrainpowder
[2]
where W represents the weight (1 mL  1 g) from the
different source, indicated by the respective subscript. The
free brain glucose ([Glc]free) and the digested glucose
([Glc]dig) were obtained and calculated from the “minus”
and “plus” samples (see above), respectively. The differ-
ence of these two from the same animal resulted in the in
vitro glycogen concentration ([Glyc]invitro).
Glycogen concentrations are expressed as mol glucosyl
units/g wet weight throughout.
1H MRS Assessment of the Isotopic Enrichment (IE) of
Glycogen (IEGlyc)
The assay samples obtained as described above were care-
fully ﬁltered with Millipore Ultrafree-CL ﬁlters (10 kDa;
Millipore Corp., MA, USA) to remove high-molecular-
weight compounds. The ﬁltered solution was frozen with
liquid N2 and lyophilized by a dual-stage rotary vane
vacuum pump (Leybold Vakuum GmbH, DE). The freeze-
dried samples were resuspended in 600 L D2O (low para-
magnetic; CIL Inc., MA, USA) for 1H MRS.
In vitro 1H NMR studies were performed in a vertical
14.1-T magnet (Oxford NMR 600, UK) equipped with an
INOVA console (Varian Inc.). 1D proton spectra without
water suppression were acquired using the following pa-
rameters: 6.7 s 90° pulse, TR  20 s, and 64 averages at
37°C. The integrals of glucose C1- proton signals were
used to determine IE based on the proton signals bound to
12C1- glucose (IH-12Cl) and
13C1- glucose (IH-13Cl), respec-
tively, using the following equation:
IE(%)
IH-13Cl
IH-13Cl 	 IH-12Cl
 100 [3]
IE was obtained by 1H MRS from the free background
glucose sample (W/O amyloglucosidase, denominated by
the subscript free) and on the digested glucose sample (W/
amyloglucosidase, denominated with the subscript dig),
respectively (see above). The IE of glycogen, IEGlyc, was
calculated from Eq. [4] with the corresponding IE, [Glc]
and [Glyc]invitro:
IEGlyc 
IEdig  [Glc]dig  IEfree  [Glc]free
[Glyc]invitro
[4]
In vitro 13C glycogen ([13C-Glyc]invitro) was calculated from
the product of [Glyc]invitro and IEGlyc.
Statistics
The experimental errors of each in vivo 13C glycogen mea-
surement were determined from all the arrayed spectra
used for ﬁnal in vivo 13C glycogen quantiﬁcation, as de-
scribed in Materials and Methods. The errors of the glyco-
gen assay were determined by two parallel measurements,
as described above. The rest of the errors in the present
studies were calculated according to the law of propaga-
tion of measurement errors, with exception of the FA
signal (Eq. [1]), glycogen phantom study, and 1H MRS
determination of IE (all of which were assumed negligi-
ble). All data are represented as the mean  SD. Signiﬁ-
cance was determined by means of a two-tailed Student’s
t-test, and a P-value  0.05 was considered statistically
signiﬁcant.
RESULTS
To achieve a high glycogen tissue content and a high
degree of 13C labeling of the glucose residues of brain
glycogen, supercompensation resulting from insulin-in-
duced acute hypoglycemia (21) was adopted in the present
studies. All 11 rats were intravenously administered 38 
5 U/kg of insulin, which resulted in acute insulin-induced
hypoglycemia (plasma glucose  1.60  0.03 mM) for
2.0  0.1 hr, followed by hyperglycemic recovery (plasma
glucose  12.0  1.3 mM) for 12.4  1.2 hr. Throughout
the in vivo experiments the animals were maintained un-
der physiological conditions (i.e., pH  7.39  0.02,
pCO2 39.6 1.9 mmHg, pO2 154.4 14.2 mmHg, and
temperature  37.1  0.1 °C).
The arrayed spectra acquired for the determination of in
vivo 13C glycogen were visually veriﬁed to be close to
steady state. The brain [1-13C]-glycogen signal was typi-
cally detected with a high SNR (Fig. 1). The external ref-
erence quantiﬁcation of in vivo 13C glycogen signal indi-
cated a modest temperature dependence of glycogen C1
signals in the oyster glycogen solution (see Materials and
Methods) and thus was applied at 37°C. The in vivo 13C
glycogen concentration ranged from 2.7 to 10.5 mol/g wet
weight, and the estimated average error of the NMR mea-
surements was SDNMR  1.3 mol/g and 2.1 mol/g.
In vitro glycogen content was determined on the same
brains as measured by in vivo NMR, resulting in total brain
glycogen concentrations ranging from 5.9 to 15.6 mol/g
FIG. 1. In vivo localized 13C NMR spectra of brain glucose and
glycogen. The spectrum shown was obtained right at the end of the
in vivo 13C MRS study and is the sum of 768 scans from 12 64-scan
interleaved spectra from a 440-L volume. The brain glycogen C1
signal is well above the noise level (SNR). Processing consisted of
20 Hz exponential multiplication, zero-ﬁlling, FFT, and phase cor-
rection. The spectrum is shown with a linear baseline correction.
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wet weight. In vitro 13C enrichment of glucose was based
on 1H MRS measurements at 14.1-T with well-resolved
12C1- glucose proton signals at 5.21 ppm and 13C1-
glucose proton signals at 5.07 and 5.35 ppm (Fig. 2). From
90% of IEfree and 81% of IEdig, an average 77% IE of
glycogen (IEGlyc) was calculated based on Eq. [4]. Multi-
plying the total enzymatic glycogen content ([Glyc]invitro)
with the IE of glycogen (IEGlyc) resulted in in vitro 1-
13C
glycogen concentrations ranging from 4.0 to 13.6 mol/g
with an average SDinvitro of 0.6 mol/g and 2.3 mol/g.
When the in vivo 13C glycogen concentration was plot-
ted as a function of in vitro 13C glycogen content (Fig. 3),
a highly linear correlation with a slope of 0.75  0.07,
mean  SE (solid line) was obtained. All but two of the
measured data points were within experimental error of
the identity line (dashed line).
DISCUSSION
In this study we used a “gold standard” method (i.e.,
amyloglucosidase assay of glycogen) to directly compare
the quantiﬁcation of brain [1-13C]-glycogen to that ob-
tained with in vivo localized 13C MRS in the same brain.
The correlation was high over a wide range of 13C glycogen
concentrations and close to identity within experimental
errors, as shown in Fig. 3.
The low 13CMRS sensitivity was compensated was com-
pensated by increasing the 13C content of brain glycogen
by inducing supercompensation as in previous studies (9),
which was adapted in this study by ﬁrst depleting brain
glycogen using insulin-induced moderate hypoglycemia
and then repleting it using 13C glucose infusions. The
ensuing supercompensation was observed in the present
study even after 12 hr of recovery both by in vivo NMR
and by biochemical methods, with an average post-hypo-
glycemic 13C glycogen level of 6.8  3.3 mol/g, conﬁrm-
ing qualitatively the ﬁndings of previous reports (9).
A higher brain 13C glycogen content led to a high SNR of
in vivo NMR signals (Fig. 1) and resulted in an excellent
estimation of in vivo 13C glycogen concentrations with
only 768 scans, which is far fewer scans than used in
previous muscle glycogen measurements (14). This was
evidenced by SDNMR  1.3 mol/g in absolute terms,
which is comparable to the error (in terms of 13C concen-
tration) observed in previous validation studies performed
in rabbit muscle (14) and liver (15), despite the fact that
brain glycogen was severalfold less concentrated. This im-
plies increases in sensitivity ascribed to improvements in
B0, RF coil design, and localization methodology. We min-
imized the potential effect of the observed temperature
dependence of glycogen signal (10% signal intensity
loss) on the accuracy of the in vivo quantiﬁcation by per-
forming the external reference at body temperature (i.e.,
37°C).
In the present study, in vitro brain glycogen was deter-
mined in the same brain tissue, obtained immediately after
the in vivo NMR measurement. Brain tissue was rapidly
ﬁxed within 1.4 s, as in previous studies by our group
(20,22) and others (6,23,24), which minimized potential
underestimation of the brain glycogen concentration due
to its rapid postmortem degradation. In particular, the
physiological conditions of the animals at the time of
ﬁxation were identical to those used when the NMR mea-
surement was performed (data not shown). In vitro 1H
NMR spectra of glucose C1- proton signals on processed
post-assay samples at 14.1-T exhibited well-resolved pro-
ton signals (Fig. 2), from which in vitro 13C glycogen
content was calculated. Despite the involved error propa-
gation SDinvitro was lower than SDNMR, especially at lower
concentrations.
The errors of both in vivo 13C glycogen signals and in
vitro 13C glycogen contents may include additional factors
beyond measurement errors, such as variations in plasma
glucose. Previous studies have shown that steady-state
plasma glucose has a linear relationship with brain glu-
cose (18,20,25–27). Given the effect of brain glucose on
FIG. 3. Comparison between in vivo and in vitro 13C glycogen
measurements. In vivo 13C glycogen concentration (vertical axis) is
plotted as a function of the 1-13C glycogen content measured
biochemically (horizontal axis). Each data point stands for one an-
imal study, and error bars represent the corresponding calculated
experimental errors. The solid line represents the best ﬁt with linear
regression (y  ax) of all data with 0.75  0.07 (R  0.79). The
dotted line is the identity line.
FIG. 2. Spectra of H1-D-glucose signals from both in vitro NMR
samples of one rat. The spectra were obtained from the “minus” (a)
and “plus” samples (b) at 14.1-T. The vertical scale was normalized
based on the intensity of the creatine CH2 peak signal at 3.93 ppm
(not shown). 13C-H1 in the ﬁgure represents the H1 protons bound
to 13C, and 12C-H1 reﬂects those protons bound to
12C.
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brain glycogen content (unpublished data; also see Refs. 9
and 22 and references therein), it is possible that variations
in the plasma glucose levels can affect brain 13C glycogen
levels. In this study, the maximum difference of plasma
glucose did not exceed 3.5 mM. However, if we exclude
data points with a plasma glucose difference higher than
1.8 mM before and after the arrayed spectra acquisition,
the slope of comparison between the two methods was
0.72 with R  0.78, which is not signiﬁcantly different
(P 
 0.05) and therefore does not affect the conclusions of
the present study.
Considering the overall variation of in vivo 13C glycogen
quantiﬁcation (SDNMR  1.3 mol/g) and one speciﬁc data
point with a standard deviation (SD) of SDinvitro 
2.3 mol/g, all points but one were within the identity line
(dashed line in Fig. 3). The excellent agreement between
the two methods is further supported by plotting the dif-
ferences of the two methods against the mean brain 13C
glycogen content (Fig. 4), in which only two differences
fall outside  2 SD (SD  2.1 mol/g of the difference,
shaded area in Fig. 4) of the line of perfect agreement
(solid line), the rest being within  2 SDNMR (SDNMR 
1.3 mol/g).
It has been reported that the T2 of glycogen is multiex-
ponential (12) and that the complex structure of glycogen
may lead to signiﬁcant fractions of the glycogen C1 reso-
nance having a substantially larger linewidth. The fact that
the slope was slightly below 1 (Fig. 3) could signify a small
overall contribution of broad resonances to the signal that
was not accounted for.
The aforementioned two forms of glycogen—proglyco-
gen and macroglycogen—appear to behave differently in
glycogen metabolism. For example, it has been reported
that proglycogen is not be actively involved in glycogen
metabolism (28) and therefore is not likely to be labeled by
13C label administration. Although in the present study the
majority of brain glycogen was depleted by the introduc-
tion of acute hypoglycemia, in principle it is possible that
some proglycogen was not depleted and completely la-
beled due to longer turnover times. This could explain the
small but signiﬁcant reduction in IE of glycogen 77%,
compared to tissue glucose 90%. This is consistent with a
previous 13C MRS study on cardiac glycogen (13).
Whatever the origin of the minor discrepancy between
the in vivo and biochemical measurements, its conse-
quence must be minimal in investigations that show large
changes in brain glycogen C1 content, as previously re-
ported (9).
We conclude that NMR measurements of brain glycogen
C1 overall reliably reﬂect the biochemically measured 13C
glycogen content. Therefore, in vivo 13C MRS in conjunc-
tion with 13C glucose infusion is an accurate and precise
method for assessing in vivo brain glycogen metabolism.
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